Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JNJ-69086420 |
Synonyms | |
Therapy Description |
JNJ-69086420 is a radiotherapy comprising an antibody targeting KLK2 (hK2) linked to actinium-225, which potentially decreases tumor growth (J Clin Oncol 42, 2024 (suppl 16; abstr 5010). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JNJ-69086420 | JNJ69086420|JNJ 69086420|JNJ-6420|JNJ6420|JNJ 6420 | JNJ-69086420 is a radiotherapy comprising an antibody targeting KLK2 (hK2) linked to actinium-225, which potentially decreases tumor growth (J Clin Oncol 42, 2024 (suppl 16; abstr 5010). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04644770 | Phase I | JNJ-69086420 | A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer | Recruiting | USA | 0 |